<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="6552">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01914003</url>
  </required_header>
  <id_info>
    <org_study_id>S2002</org_study_id>
    <nct_id>NCT01914003</nct_id>
  </id_info>
  <brief_title>Congenital Sucrase-Isomaltase Deficiency (CSID) Genetic Prevalence Study (GPS)</brief_title>
  <acronym>CSID GPS</acronym>
  <official_title>A Multi-Center Study of the Prevalence of Known Congenital Sucrase-Isomaltase Deficiency (CSID) Genetic Variants and Functional Sucrase Activity by 13C-Sucrose Breath Test in Children With Chronic Diarrhea or Chronic Abdominal Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>QOL Medical, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Arnold Palmer Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Texas Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nationwide Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ann &amp; Robert H Lurie Children</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Children's Hospital Los Angeles</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Children's Hospital and Health System  Foundation, Wisconsin</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Children's Center for Digestive Healthcare</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Duke University Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>QOL Medical, LLC</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Congenital sucrose-isomaltase deficiency (CSID) is a rare, genetic disease in which
      mutations in the sucrose-isomaltase (SI) gene cause digestion problems of sucrose resulting
      in diarrhea and abdominal pain. Children with chronic, idiopathic diarrhea or abdominal pain
      will have their sucrose-isomaltase gene assessed for a panel of known CSID mutations to
      determine the prevalence of these mutations in an enriched population and also determine
      functional deficiency using a breath test.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2013</start_date>
  <primary_completion_date type="Anticipated">January 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case Control, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Prevalence of CSID genetic variants</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Determine the prevalence of CSID genetic variants in subjects 18 years of age or younger with a primary symptom of chronic idiopathic diarrhea or chronic abdominal pain without constipation.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">1500</enrollment>
  <condition>Congenital Sucrase-isomaltase Deficiency (CSID)</condition>
  <arm_group>
    <arm_group_label>CSID Mutations</arm_group_label>
    <description>Individual has one or more known CSID mutations.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <description>Individual does not have any known CSID mutations.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        18 years of age or younger experiencing chronic, idiopathic diarrhea or abdominal pain for
        at least 4 weeks.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must be 18 years of age or younger.

          -  A primary clinical diagnosis of chronic idiopathic diarrhea or chronic abdominal pain
             for at least 4 weeks.

          -  English or Spanish speaking subjects and parent(s)/guardian only.

          -  Parental consent from one parent/guardian and also subject assent when appropriate
             based on individual IRB requirements.

        Exclusion Criteria:

          -  Any condition(s) or finding(s) that in the opinion of the principal investigator
             suggests an alternative diagnosis for his/her gastrointestinal symptoms.

          -  Abdominal pain primarily related to constipation.

          -  Suspected gastrointestinal infectious disease.

          -  No current use of sacrosidase (SucraidÂ® Oral Solution).

          -  Known gastrointestinal disease such as celiac disease.

          -  Prior consumption of an investigational medication within the last 4 weeks.

          -  Antibiotics in the last 2 weeks, and no history of viral gastroenteritis within that
             same period of time.

          -  Known Hepatitis B or C infection (positive HBsAg or HCV within 6 months of
             enrollment) or Subject-Pugh Class C liver disease of any cause, HIV infection,
             tuberculosis, Clostridia difficile co-infection, cancer or systemic infections.

          -  Severe neurologic impairment that would prevent them from reporting a history of
             abdominal pain.

          -  Receiving or received biologic therapies (including infliximab, adalimumab,
             natalizumab) within 3 months prior to or at enrollment.

          -  Present or past use of immune modulators therapy (e.g., azathioprine, 6MP,
             methotrexate).

          -  Planned or previous abdominal surgery (e.g., bowel resection).

          -  Subjects with severe, uncontrolled systemic diseases.

          -  Presence of clinical alarm signs, including hypotension, anemia requiring blood
             transfusions, altered mental status, or inability to tolerate food and/or fluids by
             mouth.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Heather Elser, PhD</last_name>
    <phone>919-832-4949</phone>
    <email>helser@qolmed.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Arnold Palmer Children's Hospital</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Devendra Mehta, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Center for Digestive Healthcare</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benjamin Gold, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Children's Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ann Scheimann, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aeri Moon, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Mercy Hospital</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joel Lim, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Duke University Children's Hospital</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Ulshen, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nationwide Children's Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carlo Di Lorenzo, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Texas Children's Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bruno Chumpitazi, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adrian Miranda, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.csidgps.com</url>
    <description>Study overview</description>
  </link>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 1, 2013</lastchanged_date>
  <firstreceived_date>July 22, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carbohydrate Metabolism, Inborn Errors</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
